ProImmune Limited Introduces ProStorm™ In-Vitro Assay Service
9/18/2012 8:49:42 AM
More...
|
ProImmune Limited Announces Launch of Special Assay Service
3/29/2012 6:57:57 AM
More...
|
ProImmune Limited Publishes White Paper 'Managing Immunogenicity Risk Through Assay-based Rational Drug Design and Selection'
11/23/2011 9:34:38 AM
More...
|
ProImmune Limited Introduces ProPresent Assay for Measurement of Antigen Processing and Presentation
9/8/2011 10:52:29 AM
More...
|
ProImmune Limited Launches ProArray Ultra: A New Protein and Peptide Microarray Platform with True Analytical Grade Performance
6/15/2011 7:08:05 AM
More...
|
ProImmune Limited Services for Measuring Cell-Mediated Immune Responses Are Now Available In Formal Compliance with GLP and GCP
10/21/2010 1:01:07 PM
More...
|
ProImmune Limited Launches Novel Class-Leading CFSE T Cell Proliferation Assays for Assessing Drug Immunogenicity Risk
12/14/2009 8:30:51 AM
More...
|
ProImmune Limited Accelerates Development of Therapeutics with REVEAL(TM) B Cell Epitope Discovery System
3/9/2009 9:56:29 AM
More...
|
ProImmune Limited Launches REVEAL(TM) Immunogenicity System Services for Development and Testing of Biologics with Reduced Immunogenicity Combines, for the First Time, Cell-Free HLA-Peptide Binding Assays for More Than 50 Class II HLA Alleles With Highly Sensitive T Cell Proliferation Assays
11/18/2008 10:15:14 AM
More...
|
ProImmune Limited Launches New MHC-Peptide Binding Assay for Class II HLA Alleles
9/24/2007 7:36:23 AM
More...
|
|